{"id":"W2091394897","doi":"10.1007/s10637-006-9009-4","title":"A phase II study of PS-341 (Bortezomib) in advanced or metastatic urothelial cancer. A trial of the Princess Margaret Hospital and University of Chicago phase II consortia","year":2006,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Ubiquitin and proteasome pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":35,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Cancer Institute","keywords":"Medicine; Bortezomib; Tolerability; Internal medicine; Phases of clinical research; Adverse effect; Metastatic Urothelial Carcinoma; Population; Cancer; Clinical trial; Chemotherapy; Response Evaluation Criteria in Solid Tumors; Oncology; Surgery; Gastroenterology; Multiple myeloma; Urothelial carcinoma; Bladder cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000154467,0.0001135442,0.000228564,0.00003908839,0.0000762602,0.000002970342,0.0001753665,0.00004906585,0.0000319102],"category_scores_gemma":[0.00009324057,0.00009292512,0.00005195853,0.0001556528,0.0002962868,0.000009074052,0.0001333861,0.00007114654,8.673692e-8],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001111358,"about_ca_system_score_gemma":0.0006373364,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000939948,"about_ca_topic_score_gemma":0.0007020558,"domain_scores_codex":[0.9990507,0.0001073705,0.0003133272,0.0002204807,0.0002007777,0.0001073537],"domain_scores_gemma":[0.9993482,0.0000280769,0.0003109319,0.0001710965,0.00008604887,0.00005565642],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.03529912,0.01288425,0.006784651,0.0001809587,0.0003159323,0.00001149355,0.006271688,0.0006260492,0.9276514,0.00162867,0.0006602873,0.007685477],"study_design_scores_gemma":[0.270084,0.02205005,0.004557119,0.0001752884,0.0002153405,0.000005338789,0.001900353,0.0002883065,0.6949354,0.002199722,0.003180298,0.0004088289],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9981121,0.0001234351,0.00002812038,0.0003097847,0.00006168286,0.0009692777,0.0003043985,0.000003021382,0.00008814455],"genre_scores_gemma":[0.999017,0.00001823472,0.000567283,0.00003159727,0.0000540744,0.00001247176,0.00004149143,0.000007707188,0.0002501566],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2347849,"threshold_uncertainty_score":0.3789376,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01672705479726409,"score_gpt":0.2777420946554259,"score_spread":0.2610150398581618,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}